Bond.az White LogoBond.az Black Logo
→
EN ▾
AZENRU
Asif Mammadov's red card costs Gabala 10,000 manatMarvell price target raised to $200 by RBC on optical strengthCreatd Boosts Vocal Stake to 51%Azercell expands digital capabilitiesStarbucks stocks pop as TD Cowen upgrades to BuyWhy is Workspace stock gaining today?Quarterhill Q1 2026: Strong GrowthPark Dental Q1 2026 Beats EPS ExpectationsXponential Fitness COO Departs CompanyShip attacked off Oman coast sinksAsif Mammadov's red card costs Gabala 10,000 manatMarvell price target raised to $200 by RBC on optical strengthCreatd Boosts Vocal Stake to 51%Azercell expands digital capabilitiesStarbucks stocks pop as TD Cowen upgrades to BuyWhy is Workspace stock gaining today?Quarterhill Q1 2026: Strong GrowthPark Dental Q1 2026 Beats EPS ExpectationsXponential Fitness COO Departs CompanyShip attacked off Oman coast sinks
Personalize
Bond.az White LogoBond.az Black Logo
AZENRU
ANALYST RATINGS

Biogen Stock Rises as Stifel Maintains Buy

Biogen stock rises as Stifel maintains buy rating. Updates on Alzheimer's drug trial and financial results.

Zoe Allen
ByZoe Allen- Senior Editor
|
0
Biogen Stock Rises as Stifel Maintains Buy
Photo: Prepared by Bond.az

Stifel maintained its Buy rating and $214 price target on Biogen (BIIB) after the company announced its BIIB080 Alzheimer's drug study missed the primary endpoint.

Shares trade at $204.53, near the 52-week high. Bond.az analysis suggests the stock remains undervalued with a fair value of $258.41.

Biogen is advancing the program, citing tau PET reductions and cognitive benefit. Stifel calls this the first true test of the tau hypothesis in Alzheimer's.

More News
Marvell price target raised to $200 by RBC on optical strength
Today / 13:32
|
872

Marvell price target raised to $200 by RBC on optical strength

RBC Capital raised Marvell Technology price target to $200, citing optical business strength. AI networking and custom XPU trends support growth.

ANALYST RATINGS →
0
Morgan Stanley Upgrades Assurant Stock Rating
Today / 13:03
|
769

Morgan Stanley Upgrades Assurant Stock Rating

Morgan Stanley upgrades Assurant stock to Overweight, raises price target to $285. Strong earnings and growth outlook highlighted.

ANALYST RATINGS →
0
Compass Point raises Nebius target to $260 on strong Q1
Today / 12:32
|
422

Compass Point raises Nebius target to $260 on strong Q1

Compass Point raised Nebius price target to $260 on strong Q1 results. ARR and AI Cloud revenue surge. Read more on Bond.az.

ANALYST RATINGS →
0
H.C. Wainwright Reiterates Immunic Stock Rating
Today / 11:44
|
476

H.C. Wainwright Reiterates Immunic Stock Rating

H.C. Wainwright maintains Buy rating and $22 price target on Immunic stock. The company awaits pivotal MS drug trial results. Read more on Bond.az.

ANALYST RATINGS →
0
H.C. Wainwright Reiterates Kamada Buy Rating
Today / 11:43
|
800

H.C. Wainwright Reiterates Kamada Buy Rating

H.C. Wainwright reaffirms Buy rating on Kamada with $13 target. Kamada expects double-digit revenue growth in 2026.

ANALYST RATINGS →
0
Titan Mining Price Target Cut by H.C. Wainwright
Today / 11:42
|
902

Titan Mining Price Target Cut by H.C. Wainwright

H.C. Wainwright cuts Titan Mining price target to $6.50, maintains Buy. Stock up 357% in a year, but Bond.az flags overvaluation risk.

ANALYST RATINGS →
0
Avino Silver & Gold Target Raised by Analyst
Today / 11:41
|
334

Avino Silver & Gold Target Raised by Analyst

H.C. Wainwright raises Avino Silver & Gold price target to $13.00 after strong earnings report with 109% revenue growth.

ANALYST RATINGS →
0
Truist reiterates Buy on Uber stock
Today / 11:05
|
279

Truist reiterates Buy on Uber stock

Truist Securities reiterates Buy on Uber stock with $112 target, citing AV strength and growth potential.

ANALYST RATINGS →
0
CrowdStrike target raised to $621 by BTIG | Bond.az
Today / 11:04
|
241

CrowdStrike target raised to $621 by BTIG | Bond.az

BTIG raises CrowdStrike stock price target to $621, citing platform growth and partner feedback. Stock up 20% YTD.

ANALYST RATINGS →
0
Truist raises CG Oncology target to $82 on NMIBC data
Today / 11:02
|
419

Truist raises CG Oncology target to $82 on NMIBC data

Truist Securities raises CG Oncology price target to $82 from $77 on NMIBC data. Stock near 52-week high after 206% yearly gain.

ANALYST RATINGS →
0
Morgan Stanley cuts Amcor price target to $42
Today / 11:01
|
308

Morgan Stanley cuts Amcor price target to $42

Morgan Stanley cuts Amcor price target to $42 from $44, citing lower EPS and EBIT forecasts. Stock near 52-week low.

ANALYST RATINGS →
0
Morgan Stanley Cuts Global-E Online Price Target
Today / 10:04
|
653

Morgan Stanley Cuts Global-E Online Price Target

Morgan Stanley cuts Global-E Online price target to $37, maintains Overweight rating. Stock near 52-week low with 15.6% weekly decline. Find more insights.

ANALYST RATINGS →
0
...